Medical Marijuana Genetics first learnt of the therapeutic properties of the cannabis plant in 2014 whilst desperately treating the symptoms of one of the founders mother’s late stage pancreatic cancer. Not long after her first dose of cannabis oil, she was able to move around relatively pain free, enabling her to tend to her beloved garden, in the weeks leading up to her death.
Medical Marijuana Genetics teamed with award winning breeders from Spain, with the initial aim of creating a line of CBD dominant cannabis strains. Using genetics from a number of well established strains, Medical Marijuana Genetics successfully created Candida (CD-1), named after the founder’s mother and meaning ‘bright light’ in Latin.
Medical Marijuana Genetics have had results ranging from 20.65% CBD with 0.7% THC to 10.65% CBD to 0.39% THC. These percentages represent the highest known consistent ratios in a CBD-rich seed strain ever created in Europe.
Medical Marijuana Genetics created a further 12 elite strains using Candida as a parent. They have selected their favourite's of these to release alongside their flagship Candida strain. These have been selected to provide access (within lawful jurisdiction) to the widest range of therapeutics that the cannabis plant, and CBD in particular, has to offer. This includes treatments for symptoms such chronic pain, inflammation, seizures, convulsions, gastro-intestinal disorders, nausea, vomiting, skin conditions, bacterial infections, anxiety, depression, cancer cell growth and much more. All of the strains that are being launched are CBD dominant and have a CBD content of over 8%, but some strains veer towards a 1:1 ratio.
In 2017 MMG strains won 5 Spannabis Champions Cups in Barcelona and Madrid. The awards include a 1st (BCN), 2nd and 3rd place (MAD) in CBD categories for Orinoco OR1, Candida CD1 and Nightingale NN1 and a 2nd and 3rd in the Indica category for as yet unreleased genetics.